Renaissance reports 4.90% stake in Corcept Therapeutics

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of common stock of Corcept Therapeutics Inc. They state beneficial ownership of 5,261,628 shares of common stock, representing 4.90% of the class.

Rhea-AI Filing Summary

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of common stock of Corcept Therapeutics Inc. They state beneficial ownership of 5,261,628 shares of common stock, representing 4.90% of the class. The filing indicates sole voting and sole dispositive power over all 5,261,628 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of these securities.

Key Figures

Shares beneficially owned: 5,261,628 shares Percent of class owned: 4.90% Sole voting power: 5,261,628 shares +1 more

4 metrics

Shares beneficially owned 5,261,628 shares Common stock of Corcept Therapeutics beneficially owned by Renaissance entities

Percent of class owned 4.90% Percentage of Corcept Therapeutics common stock class reported as beneficially owned

Sole voting power 5,261,628 shares Shares over which Renaissance reports sole power to vote or direct the vote

Sole dispositive power 5,261,628 shares Shares over which Renaissance reports sole power to dispose or direct disposition

Key Terms

beneficially owned, sole voting power, dispositive power, Schedule 13G

4 terms

beneficially owned financial

"Amount beneficially owned: 5261628"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole power to vote or to direct the vote: 5261628"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole power to dispose or to direct the disposition of: 5261628"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"Statement on , and all amendments thereto, with respect to the shares"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Corcept Therapeutics (CORT) does Renaissance Technologies report owning?

Renaissance Technologies and its affiliate report beneficial ownership of 4.90% of Corcept Therapeutics’ common stock, representing 5,261,628 shares with sole voting and dispositive power over all reported shares.

How many Corcept Therapeutics (CORT) shares does Renaissance Technologies control?

They report beneficial ownership of 5,261,628 Corcept Therapeutics common shares, with sole voting power and sole dispositive power over the same 5,261,628 shares and no shared authority.

Which entities are listed as reporting persons for the Corcept Therapeutics (CORT) Schedule 13G/A?

The reporting persons are Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation, both organized in Delaware, each reporting the same 5,261,628 shares and 4.90% beneficial ownership.

Do other parties have economic interests in Renaissance’s Corcept Therapeutics (CORT) holdings?

Yes. The filing states that certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of the Corcept Therapeutics common stock covered.

Does Renaissance report shared voting or dispositive power over Corcept Therapeutics (CORT) shares?

No. The filing lists 0 shares with shared voting power and 0 shares with shared dispositive power; all 5,261,628 shares are reported with sole power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 04:21 PM Accepted by SEC EDGAR 08/13/2026 - 04:20 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

CORCEPT THERAPEUTICS INC

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

(CUSIP Number)

04/01/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Renaissance Technologies LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,261,628.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,261,628.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,261,628.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.90 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Renaissance Technologies Holdings Corporation

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,261,628.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,261,628.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,261,628.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.90 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CORCEPT THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA 94065
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC").
(b)	Address or principal business office or, if none, residence: 520 Madison Avenue, New York, New York 10022
(c)	Citizenship: RTC is a Delaware limited liability company, and RTHC is a Delaware corporation.
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5261628
(b)	Percent of class: 4.90 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5261628
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5261628
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Certain funds managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Renaissance Technologies LLC

Signature:	Brian Felczak
Name/Title:	Chief Financial Officer
Date:	08/13/2026

Renaissance Technologies Holdings Corporation

Signature:	Brian Felczak
Name/Title:	Vice President
Date:	08/13/2026

Exhibit Information

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock, $0.001 par value of CORCEPT THERAPEUTICS INC.